Biomarker Patient-Selection Radar

Solid Tumor Oncology Edition

Benchmark how biomarkers are used for patient selection, stratification, and treatment assignment in public solid tumor oncology trials.

Built from public interventional trial text and a conservative FDA CDx mapping. Threshold fragments and patent-density signals require expert clinical and regulatory review before use — this tool does not recommend patient-selection strategies or companion diagnostic approaches.

Open methodology Request custom biomarker scan

Biomarkers tracked

22

Curated biomarker dictionary entries in the current public screen.

Contexts detected

573

Biomarker + tumor-type + drug-context combinations identified from public trial text.

Linked trials

2506

Interventional oncology trials linked into the current benchmark.

Inclusion-required contexts

493

Contexts where biomarker evidence appears to gate enrollment.

FDA CDx contexts

99

Contexts with matching local FDA companion diagnostic context.

Manual review required

168

Records that still need lower-confidence or contextual review.

Biomarker patient-selection table

Public context screen

Biomarker	Tumor type	Drug context	Role	CDx context	Thresholds	Patent density	Strategy	Confidence
PD-L1 expression	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Fragmented	Low	Manual Review Required	Low
RET fusion	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
MET exon 14 skipping	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
HER2 / ERBB2 expression	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Trial Selection Rising	Medium
PD-L1 expression	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
MET exon 14 skipping	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
CLDN18.2 expression	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
MET exon 14 skipping	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
ALK fusion	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
HER2 / ERBB2 expression	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
RET fusion	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
MET exon 14 skipping	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
ALK fusion	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Trial Selection Rising	High
KRAS G12C	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
KRAS G12D	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
RET fusion	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
MET exon 14 skipping	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
RET fusion	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
MET exon 14 skipping	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
EGFR mutation	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
EGFR exon 19 deletion	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
EGFR L858R	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
ALK fusion	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
ROS1 fusion	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
KRAS G12C	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
KRAS G12D	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
HER2 / ERBB2 expression	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
MET exon 14 skipping	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
EGFR mutation	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
EGFR exon 19 deletion	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
EGFR L858R	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
RET fusion	melanoma	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Drug Development Ahead Of Cdx Context	High
MET exon 14 skipping	melanoma	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Drug Development Ahead Of Cdx Context	High
HER2 / ERBB2 expression	breast cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
MET exon 14 skipping	breast cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Trial Selection Rising	Medium
EGFR mutation	colorectal cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
EGFR exon 19 deletion	colorectal cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
EGFR L858R	colorectal cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
HER2 / ERBB2 expression	colorectal cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
MET exon 14 skipping	colorectal cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
MET exon 14 skipping	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
CLDN18.2 expression	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
HER2 / ERBB2 expression	breast cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Low	Low	Manual Review Required	Low
PD-L1 expression	breast cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
MET exon 14 skipping	breast cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	Medium
ALK fusion	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Drug Development Ahead Of Cdx Context	Medium
MET exon 14 skipping	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
FRα / FOLR1 expression	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
RET fusion	ovarian cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Drug Development Ahead Of Cdx Context	Medium
MET exon 14 skipping	ovarian cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	Medium
PD-L1 expression	melanoma	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	Medium
MET exon 14 skipping	melanoma	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	High
RET fusion	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
MET exon 14 skipping	breast cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
HER2 / ERBB2 amplification	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	Medium
HER2 / ERBB2 expression	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Fragmented	Low	Manual Review Required	Low
BRCA1/2 mutation	ovarian cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
RET fusion	ovarian cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
MET exon 14 skipping	ovarian cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
RET fusion	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
EGFR mutation	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Fragmented	Low	Manual Review Required	Low
EGFR exon 19 deletion	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
EGFR L858R	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
PD-L1 expression	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Fragmented	Low	Manual Review Required	Low
EGFR mutation	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
EGFR exon 19 deletion	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
EGFR L858R	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
ALK fusion	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Manual Review Required	Low
HER2 / ERBB2 expression	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
RET fusion	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
BRAF V600E	colorectal cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
KRAS G12C	colorectal cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
KRAS G12D	colorectal cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
RET fusion	colorectal cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
EGFR mutation	colorectal cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Low Public Signal	Medium
EGFR exon 19 deletion	colorectal cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Low Public Signal	Medium
EGFR L858R	colorectal cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Low Public Signal	Medium
KRAS G12C	colorectal cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
KRAS G12D	colorectal cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
RET fusion	colorectal cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
MET exon 14 skipping	colorectal cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
EGFR mutation	colorectal cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Drug Development Ahead Of Cdx Context	Medium
EGFR exon 19 deletion	colorectal cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Drug Development Ahead Of Cdx Context	Medium
EGFR L858R	colorectal cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Drug Development Ahead Of Cdx Context	Medium
BRAF V600E	colorectal cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Low Public Signal	High
PD-L1 expression	colorectal cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
MSI-H / dMMR	colorectal cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
MET exon 14 skipping	colorectal cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
PD-L1 expression	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
MET exon 14 skipping	pancreatic cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	High
PD-L1 expression	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	Medium
MSI-H / dMMR	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
RET fusion	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
MET exon 14 skipping	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
PD-L1 expression	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
EGFR mutation	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
EGFR exon 19 deletion	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
EGFR L858R	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
BRAF V600E	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
HER2 / ERBB2 expression	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	High
PD-L1 expression	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
RET fusion	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
KRAS G12C	melanoma	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12D	melanoma	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
RET fusion	melanoma	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
MET exon 14 skipping	melanoma	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
EGFR mutation	melanoma	Combination Therapy	Secondary Or Exploratory	Fda Cdx Context Manual Review Required	Low	Low	Exploratory Only Signal	High
EGFR exon 19 deletion	melanoma	Combination Therapy	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
EGFR L858R	melanoma	Combination Therapy	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
ALK fusion	melanoma	Combination Therapy	Secondary Or Exploratory	Fda Cdx Context Manual Review Required	Low	Low	Exploratory Only Signal	High
BRAF V600E	melanoma	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12C	melanoma	Combination Therapy	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
KRAS G12D	melanoma	Combination Therapy	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
RET fusion	melanoma	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	High
EGFR mutation	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
EGFR exon 19 deletion	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
EGFR L858R	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
HER2 / ERBB2 expression	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Fragmented	Low	Manual Review Required	Low
ALK fusion	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
EGFR mutation	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
EGFR exon 19 deletion	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
EGFR L858R	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
MET exon 14 skipping	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
BRCA1/2 mutation	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Drug Development Ahead Of Cdx Context	Medium
HRD	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Low Public Signal	Medium
KRAS G12C	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
KRAS G12D	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
EGFR mutation	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
EGFR exon 19 deletion	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
EGFR L858R	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
KRAS G12C	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
KRAS G12D	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
RET fusion	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
MET exon 14 skipping	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Trial Selection Rising	Medium
BRAF V600E	melanoma	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Drug Development Ahead Of Cdx Context	High
PD-L1 expression	melanoma	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
RET fusion	pancreatic cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
MET exon 14 skipping	pancreatic cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
HER2 / ERBB2 expression	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Fragmented	Low	Manual Review Required	Low
RET fusion	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Trial Selection Rising	Medium
EGFR mutation	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	High
EGFR exon 19 deletion	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
EGFR L858R	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
ALK fusion	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	Medium
ROS1 fusion	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
NTRK fusion	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
BRAF V600E	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
PD-L1 expression	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
RET fusion	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
MET exon 14 skipping	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Trial Selection Rising	High
ALK fusion	breast cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Trial Selection Rising	High
BRAF V600E	breast cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
HER2 / ERBB2 expression	breast cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
RET fusion	breast cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
MET exon 14 skipping	breast cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
ALK fusion	melanoma	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
BRAF V600E	melanoma	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Drug Development Ahead Of Cdx Context	High
HER2 / ERBB2 expression	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	High
MET exon 14 skipping	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
EGFR mutation	breast cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Manual Review Required	Low
EGFR exon 19 deletion	breast cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
EGFR L858R	breast cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
RET fusion	breast cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
EGFR mutation	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
EGFR exon 19 deletion	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
EGFR L858R	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
FRα / FOLR1 expression	solid tumor basket	Small Molecule Inhibitor	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
ALK fusion	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	Medium
HER2 / ERBB2 expression	gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Cdx Established Context	Medium
MSI-H / dMMR	gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
MET exon 14 skipping	gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Trial Selection Rising	High
CLDN18.2 expression	gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	High
KRAS G12C	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12D	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
ALK fusion	pancreatic cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	Medium
HRD	colorectal cancer	Small Molecule Inhibitor	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
RET fusion	pancreatic cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	High
ALK fusion	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Trial Selection Rising	High
BRAF V600E	colorectal cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
KRAS G12C	colorectal cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
KRAS G12D	colorectal cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
MET exon 14 skipping	colorectal cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
HER2 / ERBB2 amplification	breast cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
ALK fusion	gastric cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Low Public Signal	High
PD-L1 expression	gastric cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
MSI-H / dMMR	gastric cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	Medium
RET fusion	gastric cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
MET exon 14 skipping	gastric cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
MET exon 14 skipping	ovarian cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
ROS1 fusion	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
ROS1 fusion	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
NTRK fusion	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
BRAF V600E	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
RET fusion	ovarian cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
PD-L1 expression	breast cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	Medium
HER2 / ERBB2 expression	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Trial Selection Rising	Medium
RET fusion	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
IDH1 mutation	solid tumor basket	Therapy Not Normalized	Resistance Subgroup	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
PD-L1 expression	breast cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
RET fusion	breast cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
PD-L1 expression	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Fragmented	Low	Manual Review Required	Low
ALK fusion	ovarian cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Trial Selection Rising	High
ALK fusion	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Drug Development Ahead Of Cdx Context	Medium
ROS1 fusion	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
PD-L1 expression	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
HER2 / ERBB2 amplification	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	Medium
PD-L1 expression	colorectal cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
ALK fusion	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	High
MET exon 14 skipping	solid tumor basket	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	High
EGFR mutation	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Manual Review Required	Low
EGFR exon 19 deletion	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
EGFR L858R	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
PD-L1 expression	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	Medium
RET fusion	breast cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
PD-L1 expression	melanoma	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Low Public Signal	Medium
RET fusion	melanoma	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
MET exon 14 skipping	melanoma	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
RET fusion	gastric cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Trial Selection Rising	High
MET exon 14 skipping	gastric cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Trial Selection Rising	Medium
BRCA1/2 mutation	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
BRAF V600E	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
PD-L1 expression	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Cdx Established Context	High
RET fusion	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Drug Development Ahead Of Cdx Context	Medium
MET exon 14 skipping	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Drug Development Ahead Of Cdx Context	High
KRAS G12C	melanoma	Small Molecule Inhibitor	Resistance Subgroup	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12D	melanoma	Small Molecule Inhibitor	Resistance Subgroup	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR mutation	colorectal cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
EGFR exon 19 deletion	colorectal cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
EGFR L858R	colorectal cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
RET fusion	colorectal cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
ALK fusion	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Trial Selection Rising	Medium
MSI-H / dMMR	colorectal cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
ALK fusion	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Trial Selection Rising	High
PD-L1 expression	breast cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Low	Low	Manual Review Required	Low
PD-L1 expression	gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
NTRK fusion	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
BRAF V600E	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
KRAS G12C	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
KRAS G12D	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
ALK fusion	pancreatic cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
MET exon 14 skipping	pancreatic cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	High
ROS1 fusion	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
EGFR mutation	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
EGFR exon 19 deletion	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
EGFR L858R	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
ALK fusion	breast cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Manual Review Required	Low
NTRK fusion	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	High
HER2 / ERBB2 expression	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Fragmented	Low	Trial Selection Rising	High
BRAF V600E	melanoma	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Drug Development Ahead Of Cdx Context	High
RET fusion	melanoma	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Drug Development Ahead Of Cdx Context	High
MET exon 14 skipping	melanoma	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Drug Development Ahead Of Cdx Context	High
KRAS G12C	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
KRAS G12D	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
MSI-H / dMMR	breast cancer	Combination Therapy	Secondary Or Exploratory	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
FGFR2 fusion	breast cancer	Combination Therapy	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
ALK fusion	melanoma	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
PD-L1 expression	melanoma	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	High
BRCA1/2 mutation	breast cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	Medium
BRAF V600E	ovarian cancer	Therapy Not Normalized	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
EGFR mutation	melanoma	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
EGFR exon 19 deletion	melanoma	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR L858R	melanoma	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
ALK fusion	breast cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Drug Development Ahead Of Cdx Context	Medium
KRAS G12C	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
KRAS G12D	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
HRD	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR mutation	breast cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Manual Review Required	Low
EGFR exon 19 deletion	breast cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
EGFR L858R	breast cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
HER2 / ERBB2 expression	breast cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
RET fusion	colorectal cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
ALK fusion	ovarian cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
PD-L1 expression	ovarian cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	High
MSI-H / dMMR	ovarian cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	High
EGFR mutation	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Trial Selection Rising	Medium
EGFR exon 19 deletion	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
EGFR L858R	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
BRAF V600E	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Low Public Signal	High
KRAS G12C	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Low Public Signal	High
KRAS G12D	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Low Public Signal	High
HER2 / ERBB2 expression	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	Medium
MSI-H / dMMR	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	High
ALK fusion	ovarian cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Trial Selection Rising	High
BRCA1/2 mutation	ovarian cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	Medium
BRAF V600E	ovarian cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12C	ovarian cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12D	ovarian cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12C	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
KRAS G12D	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
NTRK fusion	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Low Public Signal	High
ALK fusion	breast cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Trial Selection Rising	High
BRAF V600E	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Manual Review Required	Low
BRAF V600E	solid tumor basket	Monoclonal Antibody	Treatment Assignment	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
EGFR mutation	ovarian cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
EGFR exon 19 deletion	ovarian cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR L858R	ovarian cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
ALK fusion	colorectal cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
ROS1 fusion	colorectal cancer	Small Molecule Inhibitor	Unclear	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
NTRK fusion	colorectal cancer	Small Molecule Inhibitor	Unclear	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
HER2 / ERBB2 amplification	colorectal cancer	Small Molecule Inhibitor	Unclear	Fda Cdx Context Exists	Low	Low	Cdx Established Context	Medium
BRCA1/2 mutation	colorectal cancer	Small Molecule Inhibitor	Unclear	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
PD-L1 expression	melanoma	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
ROS1 fusion	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12C	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
KRAS G12D	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
EGFR mutation	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Trial Selection Rising	High
EGFR exon 19 deletion	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
EGFR L858R	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
HRD	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
BRCA1/2 mutation	melanoma	Immune Checkpoint Inhibitor	Resistance Subgroup	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
HER2 / ERBB2 amplification	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Low	Low	Manual Review Required	Low
BRAF V600E	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Drug Development Ahead Of Cdx Context	Medium
EGFR mutation	pancreatic cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	Medium
EGFR exon 19 deletion	pancreatic cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
EGFR L858R	pancreatic cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
BRCA1/2 mutation	NSCLC	Combination Therapy	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
HER2 / ERBB2 amplification	colorectal cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Low	Low	Manual Review Required	Low
HER2 / ERBB2 expression	colorectal cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	Medium
HER2 / ERBB2 expression	ovarian cancer	Therapy Not Normalized	Resistance Subgroup	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
MSI-H / dMMR	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
FGFR2 fusion	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
BRCA1/2 mutation	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Drug Development Ahead Of Cdx Context	High
IDH1 mutation	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR mutation	pancreatic cancer	Monoclonal Antibody	Secondary Or Exploratory	Fda Cdx Context Manual Review Required	Low	Low	Exploratory Only Signal	High
EGFR exon 19 deletion	pancreatic cancer	Monoclonal Antibody	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
EGFR L858R	pancreatic cancer	Monoclonal Antibody	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
ALK fusion	pancreatic cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	Medium
RET fusion	pancreatic cancer	Monoclonal Antibody	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
MET exon 14 skipping	pancreatic cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	High
BRAF V600E	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Drug Development Ahead Of Cdx Context	High
PD-L1 expression	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	High
PD-L1 expression	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
HER2 / ERBB2 amplification	gastric cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	Medium
HER2 / ERBB2 expression	gastric cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
PD-L1 expression	ovarian cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
HER2 / ERBB2 amplification	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Drug Development Ahead Of Cdx Context	Medium
PD-L1 expression	colorectal cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
HER2 / ERBB2 expression	gastric cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Cdx Established Context	Medium
RET fusion	pancreatic cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
TMB-high	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
ROS1 fusion	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
IDH1 mutation	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
PD-L1 expression	pancreatic cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	Medium
KRAS G12C	pancreatic cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12D	pancreatic cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
ROS1 fusion	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
BRAF V600E	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
PD-L1 expression	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
HER2 / ERBB2 expression	ovarian cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	Medium
HER2 / ERBB2 amplification	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Trial Selection Rising	High
HER2 / ERBB2 expression	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Trial Selection Rising	High
MSI-H / dMMR	colorectal cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
FRα / FOLR1 expression	NSCLC	Combination Therapy	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
HER2 / ERBB2 amplification	NSCLC	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Manual Review Required	Low
ALK fusion	colorectal cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Drug Development Ahead Of Cdx Context	High
ROS1 fusion	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Low Public Signal	Medium
BRAF V600E	colorectal cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
HER2 / ERBB2 expression	colorectal cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
MSI-H / dMMR	colorectal cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
EGFR mutation	solid tumor basket	ADC	Mention Only	Fda Cdx Context Manual Review Required	Low	Low	Exploratory Only Signal	Medium
EGFR exon 19 deletion	solid tumor basket	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR L858R	solid tumor basket	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
BRCA1/2 mutation	breast cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
HER2 / ERBB2 amplification	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Manual Review Required	Low
FGFR2 fusion	solid tumor basket	Combination Therapy	Primary Endpoint Related	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
NTRK fusion	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Fragmented	Low	Trial Selection Rising	Medium
FRα / FOLR1 expression	NSCLC	Small Molecule Inhibitor	Resistance Subgroup	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR mutation	colorectal cancer	ADC	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
EGFR exon 19 deletion	colorectal cancer	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR L858R	colorectal cancer	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
BRAF V600E	colorectal cancer	ADC	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
KRAS G12C	colorectal cancer	ADC	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
KRAS G12D	colorectal cancer	ADC	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
MET exon 14 skipping	colorectal cancer	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
BRAF V600E	pancreatic cancer	Combination Therapy	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
KRAS G12C	pancreatic cancer	Combination Therapy	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
KRAS G12D	pancreatic cancer	Combination Therapy	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
HER2 / ERBB2 amplification	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
EGFR mutation	breast cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
EGFR exon 19 deletion	breast cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR L858R	breast cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
FGFR2 fusion	breast cancer	Monoclonal Antibody	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
HER2 / ERBB2 expression	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Trial Selection Rising	High
FRα / FOLR1 expression	NSCLC	Immune Checkpoint Inhibitor	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
BRCA1/2 mutation	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
HER2 / ERBB2 amplification	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Low Public Signal	High
NTRK fusion	solid tumor basket	Monoclonal Antibody	Treatment Assignment	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12C	solid tumor basket	Monoclonal Antibody	Treatment Assignment	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
KRAS G12D	solid tumor basket	Monoclonal Antibody	Treatment Assignment	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
TMB-high	solid tumor basket	Monoclonal Antibody	Treatment Assignment	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
ALK fusion	melanoma	Therapy Not Normalized	Resistance Subgroup	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
ROS1 fusion	melanoma	Therapy Not Normalized	Resistance Subgroup	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
NTRK fusion	melanoma	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
MSI-H / dMMR	NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
MSI-H / dMMR	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
KRAS G12C	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Low Public Signal	High
KRAS G12D	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Low Public Signal	High
KRAS G12C	colorectal cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12D	colorectal cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
HRD	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
HER2 / ERBB2 amplification	breast cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Low	Low	Manual Review Required	Low
HER2 / ERBB2 expression	solid tumor basket	ADC	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Trial Selection Rising	High
PD-L1 expression	gastric cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
HER2 / ERBB2 amplification	gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
ALK fusion	NSCLC	ADC	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
HER2 / ERBB2 expression	NSCLC	ADC	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
RET fusion	NSCLC	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
MET exon 14 skipping	NSCLC	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
ALK fusion	gastric cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Drug Development Ahead Of Cdx Context	High
HER2 / ERBB2 amplification	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	High
EGFR mutation	gastric cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Trial Selection Rising	Medium
EGFR exon 19 deletion	gastric cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
EGFR L858R	gastric cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
HER2 / ERBB2 amplification	gastric cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	High
EGFR mutation	ovarian cancer	Small Molecule Inhibitor	Resistance Subgroup	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
EGFR exon 19 deletion	ovarian cancer	Small Molecule Inhibitor	Resistance Subgroup	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR L858R	ovarian cancer	Small Molecule Inhibitor	Resistance Subgroup	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
HER2 / ERBB2 expression	ovarian cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
CLDN18.2 expression	gastric cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
CLDN18.2 expression	gastric cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
FGFR2 fusion	gastric cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
RET fusion	gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
RET fusion	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	High
CLDN18.2 expression	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Trial Selection Rising	Medium
EGFR mutation	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
EGFR exon 19 deletion	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR L858R	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
ALK fusion	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
ROS1 fusion	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
BRAF V600E	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12C	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12D	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
HER2 / ERBB2 expression	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
FGFR2 fusion	solid tumor basket	Monoclonal Antibody	Unclear	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
EGFR mutation	NSCLC	ADC	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
EGFR exon 19 deletion	NSCLC	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR L858R	NSCLC	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
ROS1 fusion	NSCLC	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
NTRK fusion	NSCLC	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
BRAF V600E	NSCLC	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12C	NSCLC	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12D	NSCLC	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
PD-L1 expression	NSCLC	ADC	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
CLDN18.2 expression	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Manual Review Required	Low
KRAS G12C	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12D	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR mutation	gastric cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
EGFR exon 19 deletion	gastric cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR L858R	gastric cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
NTRK fusion	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Low Public Signal	High
HER2 / ERBB2 amplification	ovarian cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
EGFR mutation	gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Trial Selection Rising	High
EGFR exon 19 deletion	gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	High
EGFR L858R	gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	High
KRAS G12C	pancreatic cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12D	pancreatic cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
HER2 / ERBB2 expression	pancreatic cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
RET fusion	solid tumor basket	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
ROS1 fusion	breast cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
NTRK fusion	breast cancer	Small Molecule Inhibitor	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
HER2 / ERBB2 expression	breast cancer	ADC	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
MET exon 14 skipping	breast cancer	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
HRD	breast cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
HER2 / ERBB2 amplification	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	Medium
ALK fusion	melanoma	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
MSI-H / dMMR	melanoma	Monoclonal Antibody	Unclear	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	Medium
MSI-H / dMMR	gastric cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Fragmented	Low	Manual Review Required	Low
PD-L1 expression	colorectal cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	High
PD-L1 expression	ovarian cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
ALK fusion	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Trial Selection Rising	High
FGFR2 fusion	NSCLC	Small Molecule Inhibitor	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
HRD	ovarian cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
FGFR2 fusion	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
MSI-H / dMMR	solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
IDH1 mutation	solid tumor basket	Combination Therapy	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
PD-L1 expression	pancreatic cancer	Monoclonal Antibody	Mention Only	Fda Cdx Context Exists	Low	Low	Cdx Established Context	Medium
HRD	ovarian cancer	Small Molecule Inhibitor	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
MSI-H / dMMR	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
MSI-H / dMMR	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
MSI-H / dMMR	NSCLC	Therapy Not Normalized	Stratification	Fda Cdx Context Manual Review Required	Fragmented	Low	Manual Review Required	Low
ROS1 fusion	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
NTRK fusion	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
BRAF V600E	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Moderate	Low	Low Public Signal	High
BRCA1/2 mutation	NSCLC	Small Molecule Inhibitor	Stratification	Fda Cdx Context Not Found	Low	Low	Stratification Signal	High
TMB-high	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12C	pancreatic cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12D	pancreatic cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
PD-L1 expression	pancreatic cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
EGFR mutation	pancreatic cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
EGFR exon 19 deletion	pancreatic cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR L858R	pancreatic cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
BRCA1/2 mutation	pancreatic cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR mutation	melanoma	Immune Checkpoint Inhibitor	Resistance Subgroup	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
EGFR exon 19 deletion	melanoma	Immune Checkpoint Inhibitor	Resistance Subgroup	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR L858R	melanoma	Immune Checkpoint Inhibitor	Resistance Subgroup	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
NTRK fusion	colorectal cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
MSI-H / dMMR	ovarian cancer	Therapy Not Normalized	Mention Only	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
MSI-H / dMMR	melanoma	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	Medium
MSI-H / dMMR	breast cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Manual Review Required	Low
MSI-H / dMMR	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
KRAS G12C	gastric cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12D	gastric cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
BRAF V600E	breast cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
ALK fusion	colorectal cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Trial Selection Rising	High
MSI-H / dMMR	pancreatic cancer	Combination Therapy	Treatment Assignment	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
PD-L1 expression	pancreatic cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
MSI-H / dMMR	pancreatic cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
MET exon 14 skipping	pancreatic cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
BRAF V600E	gastric cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
BRAF V600E	gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
BRAF V600E	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
HRD	gastric cancer	Combination Therapy	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
MSI-H / dMMR	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Manual Review Required	Low
MSI-H / dMMR	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Low Public Signal	Medium
MSI-H / dMMR	breast cancer	Small Molecule Inhibitor	Mention Only	Fda Cdx Context Exists	Low	Low	Cdx Established Context	Medium
TMB-high	colorectal cancer	Small Molecule Inhibitor	Stratification	Fda Cdx Context Not Found	Low	Low	Stratification Signal	High
MSI-H / dMMR	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
TMB-high	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR mutation	breast cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High
EGFR exon 19 deletion	breast cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
EGFR L858R	breast cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
MSI-H / dMMR	breast cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
TMB-high	breast cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
BRCA1/2 mutation	breast cancer	Monoclonal Antibody	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
HRD	breast cancer	Monoclonal Antibody	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
ALK fusion	gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Manual Review Required	Moderate	Low	Low Public Signal	High
TMB-high	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
PD-L1 expression	ovarian cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
MSI-H / dMMR	ovarian cancer	Monoclonal Antibody	Secondary Or Exploratory	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
BRCA1/2 mutation	ovarian cancer	Monoclonal Antibody	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
MET exon 14 skipping	ovarian cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	High
RET fusion	ovarian cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	Medium
FRα / FOLR1 expression	ovarian cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
TMB-high	solid tumor basket	Small Molecule Inhibitor	Unclear	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
TMB-high	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
TMB-high	NSCLC	Therapy Not Normalized	Primary Endpoint Related	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
TMB-high	solid tumor basket	Immune Checkpoint Inhibitor	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
IDH1 mutation	solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
TMB-high	melanoma	Immune Checkpoint Inhibitor	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	High
HRD	ovarian cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
TMB-high	breast cancer	Combination Therapy	Treatment Assignment	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
HRD	ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
TMB-high	solid tumor basket	Therapy Not Normalized	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
CLDN18.2 expression	solid tumor basket	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
CLDN18.2 expression	pancreatic cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	Medium
CLDN18.2 expression	pancreatic cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
CLDN18.2 expression	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
CLDN18.2 expression	colorectal cancer	Therapy Not Normalized	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
HER2 / ERBB2 amplification	gastric cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
CLDN18.2 expression	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
CLDN18.2 expression	solid tumor basket	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
CLDN18.2 expression	pancreatic cancer	Monoclonal Antibody	Secondary Or Exploratory	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
FGFR2 fusion	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
IDH1 mutation	gastric cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
FRα / FOLR1 expression	ovarian cancer	Immune Checkpoint Inhibitor	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
FRα / FOLR1 expression	pancreatic cancer	Therapy Not Normalized	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
FRα / FOLR1 expression	NSCLC	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
FRα / FOLR1 expression	ovarian cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
FRα / FOLR1 expression	solid tumor basket	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
BRCA1/2 mutation	ovarian cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
FRα / FOLR1 expression	NSCLC	Therapy Not Normalized	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
FRα / FOLR1 expression	ovarian cancer	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Trial Selection Rising	Medium
FRα / FOLR1 expression	breast cancer	Therapy Not Normalized	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Manual Review Required	Low
FRα / FOLR1 expression	ovarian cancer	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
FRα / FOLR1 expression	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
PD-L1 expression	ovarian cancer	ADC	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
RET fusion	ovarian cancer	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
MET exon 14 skipping	ovarian cancer	ADC	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
FRα / FOLR1 expression	ovarian cancer	ADC	Resistance Subgroup	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
FRα / FOLR1 expression	breast cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	Medium
FRα / FOLR1 expression	breast cancer	Combination Therapy	Mention Only	Fda Cdx Context Not Found	Low	Low	Exploratory Only Signal	Medium
NTRK fusion	solid tumor basket	Combination Therapy	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
HER2 / ERBB2 amplification	NSCLC	Combination Therapy	Inclusion Required	Fda Cdx Context Manual Review Required	Low	Low	Low Public Signal	High

Enrollment-required biomarkers

Selection signals

PD-L1 expression: PD-L1 expression is flagged as manual review required because public trials show inclusion required evidence in 75 contexts. FDA CDx context should be reviewed manually. Threshold text varies across public records.
RET fusion: RET fusion is flagged as manual review required because public trials show inclusion required evidence in 155 contexts. FDA CDx context should be reviewed manually.
MET exon 14 skipping: MET exon 14 skipping is flagged as manual review required because public trials show inclusion required evidence in 313 contexts. FDA CDx context should be reviewed manually. Threshold text varies across public records.
HER2 / ERBB2 expression: HER2 / ERBB2 expression is flagged as trial selection rising because public trials show inclusion required evidence in 5 contexts. FDA CDx context should be reviewed manually.
PD-L1 expression: PD-L1 expression is flagged as manual review required because public trials show inclusion required evidence in 83 contexts. FDA CDx context exists.

Stratification signals

Subgroup balancing

MSI-H / dMMR: MSI-H / dMMR is flagged as manual review required because public trials show stratification evidence in 3 contexts. FDA CDx context should be reviewed manually. Threshold text varies across public records.
BRCA1/2 mutation: BRCA1/2 mutation is flagged as stratification signal because public trials show stratification evidence in 2 contexts. FDA CDx context should be reviewed manually.
TMB-high: TMB-high is flagged as stratification signal because public trials show stratification evidence in 1 contexts. FDA CDx context should be reviewed manually.

FDA CDx context

Mapped contexts

PD-L1 expression: PD-L1 expression is flagged as manual review required because public trials show inclusion required evidence in 83 contexts. FDA CDx context exists.
ALK fusion: ALK fusion is flagged as manual review required because public trials show inclusion required evidence in 70 contexts. FDA CDx context exists. Threshold text varies across public records.
EGFR mutation: EGFR mutation is flagged as manual review required because public trials show inclusion required evidence in 187 contexts. FDA CDx context exists. Threshold text varies across public records.
ALK fusion: ALK fusion is flagged as manual review required because public trials show inclusion required evidence in 76 contexts. FDA CDx context exists. Threshold text varies across public records.
EGFR mutation: EGFR mutation is flagged as manual review required because public trials show inclusion required evidence in 122 contexts. FDA CDx context exists. Threshold text varies across public records.

Drug development ahead of CDx context

Review queue

RET fusion: RET fusion is flagged as drug development ahead of cdx context because public trials show inclusion required evidence in 13 contexts. FDA CDx context should be reviewed manually.
MET exon 14 skipping: MET exon 14 skipping is flagged as drug development ahead of cdx context because public trials show inclusion required evidence in 16 contexts. FDA CDx context should be reviewed manually.
ALK fusion: ALK fusion is flagged as drug development ahead of cdx context because public trials show inclusion required evidence in 20 contexts. FDA CDx context should be reviewed manually.
RET fusion: RET fusion is flagged as drug development ahead of cdx context because public trials show inclusion required evidence in 14 contexts. FDA CDx context should be reviewed manually.
EGFR mutation: EGFR mutation is flagged as drug development ahead of cdx context because public trials show inclusion required evidence in 8 contexts. FDA CDx context should be reviewed manually.

Sponsor-biomarker matrix

Sponsor views

23andMe, Inc.: 3 linked contexts
3D Medicines (Sichuan) Co., Ltd.: 6 linked contexts
4D pharma plc: 3 linked contexts
7 Hills Pharma, LLC: 7 linked contexts
A2 Biotherapeutics Inc.: 1 linked contexts
Abbisko Therapeutics Co, Ltd: 5 linked contexts

Biomarker pages

Dictionary views

Biomarker access

Receive Biomarker Updates by Email

Use this form to compare biomarker patient-selection strategies, subscribe for email updates, choose CSV interests, or request a tumor-type-specific benchmark.